Shots: The P-III ATLANTIS study involves assessing Zepzelca (lurbinectedin, 2.0mg/m2) + doxorubicin vs topotecan/ CAV in 613 adult patients in a ratio (1:1) aged ≥18yrs. with SCLC whose disease progressed […]readmore
Tags : PharmaMar
1. Janssen to Present Updated Results of JNJ-4528 in P-Ib/II CARTITUDE-1 Study for Multiple Myeloma at ASCO 2020 Published: May 14, 2020 | Tags: Janssen, Update, Results, JNJ-4528, P-Ib/II, CARTITUDE-1, Study, […]readmore
Shots: MegaPharm to get exclusive commercialization rights for Lurbinectedin in Israel and PharmaMar to retain production rights for the product The focus of the agreement is to strengthen MegaPharm’s oncology […]readmore
Shots: The US FDA has accepted NDA filing with PR seeking accelerated approval for lurbinectedin to treat patients with SCLC having diseases progression following the prior treatment of platinum-containing therapy […]readmore
Shots: Lurbinectedin (PM1183) a compound under clinical investigation an inhibitor of RNA polymerase II, essential for transcription process that is over-activated in tumors with transcription addiction The designation may provide […]readmore